Kyowa Hakko Kirin Co., Limited

E. R. Squibb Sons, Inc.

Medarex Inc.

Kirin Beer Kabushiki Kaisha

Kirin Pharma Kabushiki Kaisha

Kirin Holdings Kabushiki Kaisha

Tottori University

Kyowa Kirin Co., Ltd.

Kirin Brewery Company, Limited

Arca Biopharma, Inc.

Chromocenter Inc.

Hematech, LLC

National University Corporation Tottori University

Kazuma Tomizuka

Isao Ishida

Yoshimi Kuroiwa

Hitoshi Yoshida

James M Robl

Mitsuo Oshimura

Nils Lonberg

Edward L Halk

Kazunori Hanaoka

Barbara A Osborne

Richard A Goldsby

Poothappillai Kasinathan

Makoto Kakitani

Yasuhiro Kazuki

Takeshi Oshima

Stacy E Ferguson

Minoru Kakeda

Walter D Funk

Philippe Collas

Takashi Matsuoka

Eddie Sullivan

Mikio Yagi

Motonobu Katoh

Eun Ju Park

Ed Halk

P Kasinathan

This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of increasing bone mass, bone density, and/or bone strength, or a mutant of such domain having sequence identity of 85% or higher to the amino acid sequence of the domain and having activity of increasing bone mass, bone density, and/or bone strength, or a vector comprising a nucleic acid encoding the protein.

Pharmaceutical composition for treating bone diseases which comprises protein comprising Frizzled 1, Frizzled 2 or Frizzled 7 extracellular cysteine-rich domain

The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody &#x3bb; light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the nonhuman animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.

Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission

The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.

Transgenic transchromosomal rodents for making human antibodies

Pharmaceutical composition for treating bone diseases which comprises protein comprising Frizzled1, Frizzled2 or Frizzled7 extracellular cysteine-rich domain

Human artificial chromosome containing human antibody &#x3bb; light chain gene and non-human animal containing the human artificial chromosome  capable of genetic transmission

This invention relates to a mammalian artificial chromosome vector, which retains a human chromosome 7 fragment comprising human cytochrome P450 genes and is transmittable to progeny, wherein the human chromosome 7 fragment retains a region of approximately 1 Mb&#xb1;500 Kb in size comprising at least a human CYP3A gene cluster, which region is located between chromosome markers AC004922 and AC073842, and to a non-human mammalian animal retaining the vector.

Mammalian artificial chromosome vector comprising human cytochrome P450 gene (cluster) and non-human mammalian animal retaining the same

Transgenic trasnchromosomal rodents for making human antibodies

This invention relates to a human artificial chromosome (HAC) vector carrying a human chromosome-derived centromere, a subtelomere sequence, and a telomere sequence, to a human cell medicine or human cells comprising the HAC vector, to methods for preparing the HAC vector and human cells, and to methods for producing a therapeutic protein using the HAC vector.

Human artificial chromosome (HAC) vector and human cell medicine comprising same

The present invention relates to a human artificial chromosome (HAC) vector and a method for producing the same. The present invention further relates to a method for introducing foreign DNA using a human artificial chromosome vector and a method for producing a cell which expresses foreign DNA. Furthermore, the present invention relates to a method for producing a protein.

Human artificial chromosome (HAC) vector

The present invention relates to a method for producing a modified foreign chromosome(s) or a fragment(s) thereof, which comprises the steps of: (a) preparing a microcell comprising a foreign chromosome(s) or a fragment(s) thereof, and transferring said foreign chromosome(s) or a fragment(s) into a cell with high homologous recombination efficiency through its fusion with said microcell; (b) in said cell with high homologous recombination efficiency, inserting a targeting vector by homologous recombination into a desired site of said foreign chromosome(s) or a fragment(s) thereof, and/or a desired site of a chromosome(s) derived from said cell with high homologous recombination efficiency, thereby marking said desired site; and (c) in said cell with high homologous recombination efficiency, causing deletion and/or translocation to occur at the marked site of said foreign chromosome(s) or a fragment(s) thereof.

Method for modifying chromosomes

The specification relates to a method for producing a chimeric non-human animal, which comprises preparing a microcell containing a foreign chromosome(s) or a fragment(s) thereof and transferring the foreign chromosome(s) or fragment(s) thereof into a pluripotent cell by fusion with the microcell; a chimeric non-human animal which can be produced by the above method and its progeny; tissues and cells derived therefrom; and a method for using the same. Further, a pluripotent cell containing a foreign chromosome(s) or a fragment(s) thereof, a method for producing the same, and a method for using the same are also provided. Moreover, a pluripotent cell in which at least two endogenous genes are disrupted, and a method for producing the same by homologous recombination are provided.

Isolated human chromosome 14 fragment encoding immunoglobulin genes

The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor (GIPF) polynucleotides and polypeptides. The invention further relates to the therapeutic use of GIPF to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa.

Method of stimulating epithelial cell proliferation by administration of gastrointestinal proliferative factor

In general, the invention features genetically modified non-human mammals (e.g., bovines and other ungulates), and methods of making these mammals. In particular, the invention features transgenic ungulates having reduced levels of endogenous IgM heavy chain and/or prion protein.

Method of producing xenogenous antibodies using a bovine

Growing community of inventors

Takasaki, Japan

Kazuma Tomizuka